David Doležil

1.5k total citations · 1 hit paper
27 papers, 992 citations indexed

About

David Doležil is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, David Doležil has authored 27 papers receiving a total of 992 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 13 papers in Pathology and Forensic Medicine and 4 papers in Neurology. Recurrent topics in David Doležil's work include Migraine and Headache Studies (18 papers), Trigeminal Neuralgia and Treatments (7 papers) and Attention Deficit Hyperactivity Disorder (3 papers). David Doležil is often cited by papers focused on Migraine and Headache Studies (18 papers), Trigeminal Neuralgia and Treatments (7 papers) and Attention Deficit Hyperactivity Disorder (3 papers). David Doležil collaborates with scholars based in United States, Germany and Denmark. David Doležil's co-authors include Daniel D. Mikol, Messoud Ashina, Uwe Reuter, Stewart J. Tepper, Jan Lewis Brandes, Robert Lenz, Paul Winner, Stephen D. Silberstein, Jan Klatt and Sunfa Cheng and has published in prestigious journals such as Neurology, The Lancet Neurology and JAMA Neurology.

In The Last Decade

David Doležil

22 papers receiving 966 citations

Hit Papers

Safety and efficacy of erenumab for preventive treatment ... 2017 2026 2020 2023 2017 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
    2017 538 citations Stewart J. Tepper, Messoud Ashina et al. The Lancet Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Doležil United States 10 914 657 336 103 93 27 992
Yngve Hallström United States 8 807 0.9× 492 0.7× 265 0.8× 137 1.3× 65 0.7× 11 964
Tricia Blankenbiller United States 4 893 1.0× 620 0.9× 367 1.1× 87 0.8× 60 0.6× 8 962
Jo Bonner United States 8 782 0.9× 522 0.8× 297 0.9× 63 0.6× 62 0.7× 11 868
Jan Klatt United States 18 1.3k 1.4× 926 1.4× 490 1.5× 134 1.3× 107 1.2× 43 1.4k
Melissa Grozinski‐Wolff United States 5 1.2k 1.3× 808 1.2× 465 1.4× 116 1.1× 77 0.8× 7 1.2k
Hille Koppen Netherlands 15 768 0.8× 472 0.7× 237 0.7× 123 1.2× 100 1.1× 40 1.0k
Ernesto Aycardi United States 14 1.2k 1.3× 846 1.3× 509 1.5× 108 1.0× 74 0.8× 32 1.4k
Kevin Shields United Kingdom 11 695 0.8× 496 0.8× 378 1.1× 87 0.8× 47 0.5× 14 885
Davinia Larrosa Spain 10 741 0.8× 455 0.7× 332 1.0× 207 2.0× 77 0.8× 34 902
César Ramón Spain 11 768 0.8× 473 0.7× 330 1.0× 226 2.2× 79 0.8× 18 922

Countries citing papers authored by David Doležil

Since Specialization
Citations

This map shows the geographic impact of David Doležil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Doležil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Doležil more than expected).

Fields of papers citing papers by David Doležil

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Doležil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Doležil. The network helps show where David Doležil may publish in the future.

Co-authorship network of co-authors of David Doležil

This figure shows the co-authorship network connecting the top 25 collaborators of David Doležil. A scholar is included among the top collaborators of David Doležil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Doležil. David Doležil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tepper, Stewart J., David W. Dodick, Michel Lantéri‐Minet, et al.. (2024). Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine. JAMA Neurology. 81(11). 1140–1140. 7 indexed citations
2.
Pozo‐Rosich, Patricia, David Doležil, Koen Paemeleire, et al.. (2024). Early Use of Erenumab vs Nonspecific Oral Migraine Preventives. JAMA Neurology. 81(5). 461–461. 16 indexed citations
3.
Pozo‐Rosich, Patricia, Holland C. Detke, Shufang Wang, et al.. (2022). Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Current Medical Research and Opinion. 38(5). 731–742. 22 indexed citations
4.
Ashina, Messoud, Stewart J. Tepper, Jan Lewis Brandes, et al.. (2022). Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis. Headache The Journal of Head and Face Pain. 62(5). 624–633. 3 indexed citations
5.
Reuter, Uwe, Christian Lucas, David Doležil, et al.. (2021). Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial. Advances in Therapy. 38(11). 5465–5483. 22 indexed citations
6.
Doležil, David, et al.. (2020). <p>An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study</p>. Journal of Pain Research. Volume 13. 2895–2906. 1 indexed citations
7.
8.
Nežádal, Tomáš, et al.. (2020). The International Classification of Headache Disorders (ICHD-3) – the official Czech translation. Česká a slovenská neurologie a neurochirurgie. 83/116(2). 145–152. 2 indexed citations
9.
Tepper, Stewart J., Messoud Ashina, Uwe Reuter, et al.. (2019). Assessment of the Long-Term Safety and Efficacy of Erenumab During Open-Label Treatment of Patients With Chronic Migraine (P1.10-016). Neurology. 92(15_supplement).
10.
Detke, Holland C., Patricia Pozo‐Rosich, Uwe Reuter, et al.. (2019). One-Year Treatment with Galcanezumab in Patients with Chronic Migraine: Results from the Open-Label Phase of the REGAIN Study (P2.10-010). Neurology. 92(15_supplement). 12 indexed citations
11.
Tepper, Stewart J., Katherine L. Widnell, David Doležil, et al.. (2017). Evaluating the Efficacy and Safety of Erenumab (AMG 334) In Chronic Migraine Prevention in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study (S52.002). Neurology. 88(16_supplement). 1 indexed citations
12.
Tepper, Stewart J., Messoud Ashina, Uwe Reuter, et al.. (2017). Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology. 16(6). 425–434. 538 indexed citations breakdown →
13.
Řasová, Kamila, David Doležil, Petr Kučera, et al.. (2012). Physiotherapy as an immunoactive therapy? A pilot study.. PubMed. 33(1). 67–75. 4 indexed citations
14.
Doležil, David, et al.. (2012). Hypnic headache - a rare primary headache disorder with very good response to indomethacin.. PubMed. 33(6). 597–9. 3 indexed citations
15.
Bartoš, Aleš, et al.. (2011). Alzheimerova nemoc a mírná kognitivní porucha: diagnostika a léčba. Neurologie pro praxi. 12(3). 175–180. 1 indexed citations
16.
Sobek, Ondřej, et al.. (2009). Vyšetření likvoru - současné možnosti. Neurologie pro praxi. 10(5). 280–284. 1 indexed citations
17.
18.
Adam, P., et al.. (2009). Eosinophilic meningitis — an immunophenotyping recording of a very rare clinical entity — Brief Report. Folia Microbiologica. 54(3). 257–260. 3 indexed citations
19.
Doležil, David, et al.. (2007). Vegetativní stav (apalický syndrom). Neurologie pro praxi. 8(1). 27–31.
20.
Doležil, David. (2005). Diferenciální diagnóza a terapie bolestí hlavy. Interní medicína pro praxi. 4(4). 188–192.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yngve Hallström Breakdown of academic impact, for papers by Tricia Blankenbiller Breakdown of academic impact, for papers by Jo Bonner Breakdown of academic impact, for papers by Jan Klatt Breakdown of academic impact, for papers by Melissa Grozinski‐Wolff Breakdown of academic impact, for papers by Hille Koppen Breakdown of academic impact, for papers by Ernesto Aycardi Breakdown of academic impact, for papers by Kevin Shields Breakdown of academic impact, for papers by Davinia Larrosa Breakdown of academic impact, for papers by César Ramón
Rankless by CCL
2026